Pasteur Institute of Lille

What Pasteur Institute of Lille does

The Pasteur Institute of Lille (Institut Pasteur de Lille) is a private, non-profit foundation recognized as a French public utility since 1898, headquartered at 1 Rue du Professeur Calmette in Lille. It operates an integrated biomedical research and prevention platform comprising 34 research teams across 8 research units covering infectious diseases, chronic diseases, cancers, neurodegenerative diseases, cardiovascular and metabolic diseases, and environmental health — notably the original developers of the BCG tuberculosis vaccine in 1921 and currently advancing the BPZE1 nasal pertussis vaccine in clinical development. The research engine is supported by shared technological platforms including BICeL (BioImaging), ARIADNE-Screening for drug discovery, P3M (Proteomics), Bille (Bioinformatics), TAG (Transcriptomics/Genomics), and LIGAN MP (Genomics), and is delivered through joint research units with CNRS and Inserm in collaboration with the University of Lille, CHU de Lille, and Imperial College London.

The institute operates a portfolio of prevention and education services alongside its research, including a Prevention Center network with locations in Lille, Tourcoing, Arras, and Béthune offering health assessments and vaccinations; a WHO-accredited International Vaccination Center providing travel medicine through the Métis system; a public Pasteur Institute Museum on Boulevard Louis XIV; the 'Le 1894' venue for professional events; the Vipali digital prevention tool; and the Kid Campus school program serving 300+ CM1-CM2 students annually. Its revenue model is hybrid and non-commercial in orientation, combining individual donations (eligible for a 66% French tax deduction), legacies and inheritances, corporate sponsorship (mécénat), apprenticeship tax contributions, museum admission fees (€6/€3), prevention and vaccination service fees, GLP-certified toxicology testing, and campus-based biotech company partnerships.

Seven biotech companies (Bioversys, Genoscreen, Apteeus, 4P-Pharma, Immune Insight, Lifebloom, StarkAge) are hosted on campus to commercialize research outputs, and the institute serves as the Europe regional coordinator of the International Network of Pasteur Institutes (RIIP), which comprises 32 institutes across 25 countries. Leadership was refreshed in 2024 with Frédéric Batteux appointed as Director General on 1 September 2024 and Perrine Quivron as Deputy Director General in December 2024.

Name

Pasteur Institute of Lille

Legal name

Institut Pasteur de Lille

Website

https://pasteur-lille.fr

Company type

Private

Founded year

1894

Operating status

Operating

Headcount range

251–500 employees

Short description

The Pasteur Institute of Lille is a French non-profit research foundation, founded in 1894 and recognized as a public utility since 1898, that conducts biomedical research across infectious, chronic, neurodegenerative, and metabolic diseases through 34 teams in 8 units, while operating regional prevention and vaccination centers, a public museum, and a portfolio of campus-based biotech spinouts.

Ownership category

akta.pro rank

Product category

Medical Research and Preventive Health Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• Biomedical research
• Preventive health services
• Vaccination services
• Drug discovery
• Medical research foundation

Headquarters

HQ city

Lille

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Donations: Individual donations with tax reduction benefits (66% tax deduction up to 20% of taxable income). Suggested donation amounts of €50, €75, €150, €250.
2. Legacies and Inheritances: Bequests and legacy donations as part of heritage transmission options
3. Corporate Sponsorship (Mécénat): Corporate sponsorship programs for companies supporting medical research
4. Apprenticeship Tax: Corporate apprenticeship tax contributions (Taxe d'apprentissage)
5. Museum and Event Services: Museum admission fees (€6 full price, €3 reduced), venue rental for professional events at 'Le 1894' space, group reservations
6. Vaccination and Health Services: International vaccination center services with consultation fees, price list available for travel vaccinations
7. Prevention Center Services: Health assessments and examinations at Prevention Center locations in Lille, Tourcoing, Arras, and Béthune

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

The Pasteur Institute of Lille is a non-profit medical research foundation operating 8 research units with 34 teams conducting fundamental and applied biomedical research on infectious, chronic, neurodegenerative, metabolic and cardiovascular diseases. It delivers prevention services (vaccination, travel medicine, health check-ups) through a network of Prevention Centers in Lille, Tourcoing, Arras and Béthune, runs a Drug Discovery Center, GLP/BPL toxicology testing, the Pasteur Institute Museum, and the Kid Campus science education program.

Product overview

The Pasteur Institute of Lille operates as an integrated medical research foundation offering a comprehensive portfolio combining fundamental and applied research across 8 research units with 34 teams, prevention services through its Health Prevention Center network, specialized technological platforms, and regulatory testing services. The institute also hosts biotechnology companies on its campus and provides educational programs. Key offerings include the Drug Discovery Center for therapeutic development, GLP-certified toxicology testing, WHO-accredited International Vaccination Center, and digital health tools like Vipali. The research portfolio spans infectious diseases, cancers, neurodegenerative diseases, cardiovascular/metabolic diseases, with technology platforms supporting bioimaging, screening, proteomics, bioinformatics, and animal experimentation.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Research Services Fundamental and applied research services across infectious diseases, chronic diseases, cancers, neurodegenerative diseases, metabolic and cardiovascular diseases, conducted by 34 research teams within 8 research units.
• Prevention Center Services Health prevention services including vaccination and travel medicine, health check-ups and examinations, and health education, delivered through centers in Lille, Tourcoing, Arras, and Béthune.
• International Vaccination Center WHO-accredited vaccination center specializing in travel medicine, providing consultations, vaccinations, and travel health advice through the Métis system.
• Health Check-up Center Personalized medical examinations and health assessments for disease prevention and early risk identification, with appointments available via Doctolib.
• Drug Discovery Center (U1177) Research unit specialized in creating and modeling molecules and chemical components for therapeutic purposes, supporting drug candidate development for promising therapeutic targets.
• GLP/BPL Regulatory Toxicology Testing Standard regulatory toxicology tests under GLP conditions, including genotoxicity testing and cosmetology-specific tests conducted by the Laboratory of Genetic Toxicology.
• Microbiological Safety Unit (USM/MSU) Expertise unit evaluating disinfection systems effectiveness and conducting microbiological analyses under controlled conditions.
• Pasteur Institute Museum Museum showcasing the history of the Institute, its founders, and scientific discoveries, with self-guided tours via the Wivisites audio guide application. Open on weekends and by reservation for groups.
• Le 1894 Event Venue Professional event venue at the Pasteur Institute of Lille for hosting conferences, symposiums, and corporate events.
• Kid Campus Program Science education program for CM1-CM2 students offering hands-on laboratory workshops and museum visits to raise awareness about research, reaching 300+ students annually.
• Vipali Digital Prevention Tool Digital health prevention solution assessing lifestyle factors (diet, physical activity, sleep, well-being) to provide personalized recommendations supporting behavior change.
• Longevity Path (Chemin Longévité) Innovative preventive medicine approach focused on healthy longevity, expanding regionally with corporate partnerships.

Quantifiable outcome

• 91 genome regions associated with Alzheimer's disease risk identified, including 16 new regions
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

17 partnerships are on record, tiered core and minor.

• International Network of Pasteur Institutes (RIIP)coreStrategic or Co-development Partner · 1 November 2018The Pasteur Institute of Lille coordinates the Europe region within the RIIP, which comprises 32 institutes across 25 countries. This global network is dedicated to protecting human health through research, training, and surveillance of infectious and chronic diseases.
• StarkAge TherapeuticscoreStrategic or Co-development Partner · 1 January 2018Biotech focused on delaying progression of age-related diseases by targeting senescent cells, founded by Dr. Thierry Mathieu
• 4P-PharmacoreStrategic or Co-development Partner · 1 July 2016Clinical-stage biotech dedicated to serious diseases with unmet medical needs, launched in July 2016
• Immune InsightminorStrategic or Co-development Partner · 1 January 2016Startup offering preclinical validation of drug candidate safety regarding immune cells and regulatory T lymphocytes
• ApteeuscoreStrategic or Co-development Partner · 1 January 2013Personalized medicine company for rare and orphan diseases, founded by Benoît Déprez from Drug Discovery Center U1177
• GenoscreencoreStrategic or Co-development Partner · 1 January 2001Biotechnology company founded on campus in 2001, offering genomics services and bioinformatics solutions for academic and industrial research
• University of LillecoreStrategic or Co-development PartnerAcademic partnership for joint research programs in metabolic diseases, diabetes, and biomedical research
• Imperial College LondoncoreStrategic or Co-development PartnerInternational collaboration on pancreatic aging and diabetes research
• CNRS (National Centre for Scientific Research)coreStrategic or Co-development PartnerJoint research units including UMR9031, U1011, U1283/8199 for metabolic and cardiovascular diseases
• Inserm (National Institute of Health and Medical Research)coreStrategic or Co-development PartnerMultiple joint research units (U1167, U1011, U1283, U1190, U1177) focusing on chronic diseases, diabetes, metabolic diseases, and drug discovery
• Lille University Hospital (CHU de Lille)coreStrategic or Co-development PartnerClinical research collaboration and translational research on diabetes and metabolic diseases
• Bioversys SAScoreStrategic or Co-development PartnerSubsidiary of Swiss BioVersys AG focusing on small molecules targeting bacterial resistance, with R&D in Unit U1177 in collaboration with GSK and University of Lille consortium
• European Metropolis of Lille (MEL)coreStrategic or Co-development PartnerInstitutional partner represented on Board of Directors through Vice-President Arnaud Deslandes
• Hauts-de-France Regional CouncilcoreStrategic or Co-development PartnerInstitutional partner represented on Board of Directors through Vice-President Manoëlle Martin
• Nord Departmental CouncilminorStrategic or Co-development PartnerInstitutional partner represented on Board of Directors through Councillor Charlotte Lecocq Parmentier
• GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerCollaboration with Bioversys SAS on tuberculosis drug development programs
• Yasmine Belkaid (Director General of Pasteur Institute of Paris)coreStrategic or Co-development PartnerInstitutional partner on Board of Directors representing the global Pasteur Network

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/pasteurlille
• YouTubeyoutube.com/user/PasteurLilleTv
• Facebookfacebook.com/pasteurlille
• LinkedInlinkedin.com/company/institut-pasteur-de-lille
• Instagraminstagram.com/pasteur_lille

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pasteur Institute of Lille